Search results

719 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Public health guidelines Remove Public health guidelines filter

Subarachnoid haemorrhage due to ruptured aneurysms

In development [GID-NG10097] Expected publication date: 21 July 2021

Type

NICE guideline

Status

In development
Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 22 June 2022

Type

NICE guideline

Status

In development
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

In development [GID-NG10091] Expected publication date: 21 April 2021

Type

NICE guideline

Status

In development
Barrett's oesophagus: medical management, endoscopic treatment, follow up and stage 1 adenocarcinoma

In development [GID-NG10165] Expected publication date: 23 January 2023

Type

NICE guideline

Status

In development
Depression in adults: treatment and management (update)

In development [GID-CGWAVE0725] Expected publication date: 12 May 2022

Type

NICE guideline

Status

In development
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management

In development [GID-NG10185] Expected publication date: TBC

Type

NICE guideline

Status

In development
Intrapartum care for healthy women and babies (update)

In development [GID-NG10174] Expected publication date: 22 March 2023

Type

NICE guideline

Status

In development
Neonatal infection: antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 13 April 2021

Type

NICE guideline

Status

In development
Heart valve disease presenting in adults: investigation and management

In development [GID-NG10122] Expected publication date: 08 September 2021

Type

NICE guideline

Status

In development
Inducing labour (update)

In development [GID-NG10082] Expected publication date: 14 October 2021

Type

NICE guideline

Status

In development
Caesarean section (update)

In development [GID-NG10081] Expected publication date: 31 March 2021

Type

NICE guideline

Status

In development
Rehabilitation after traumatic injury

In development [GID-NG10105] Expected publication date: 23 November 2021

Type

NICE guideline

Status

In development
Self harm: assessment, management and preventing recurrence

In development [GID-NG10148] Expected publication date: 18 May 2022

Type

NICE guideline

Status

In development
Gout: diagnosis and management

In development [GID-NG10151] Expected publication date: 13 June 2022

Type

NICE guideline

Status

In development
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

In development [GID-NG10098] Expected publication date: TBC

Type

NICE guideline

Status

In development
Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10186] Expected publication date: TBC

Type

NICE guideline

Status

In development
Rehabilitation for Chronic Neurological Disorders Including Traumatic Brain Injury

In development [GID-NG10181] Expected publication date: TBC

Type

NICE guideline

Status

In development
Weight Management

In development [GID-NG10182] Expected publication date: 22 June 2023

Type

NICE guideline

Status

In development
Postnatal care

In development [GID-NG10070] Expected publication date: 13 April 2021

Type

NICE guideline

Status

In development
Pernicious anaemia

In development [GID-NG10176] Expected publication date: 23 March 2023

Type

NICE guideline

Status

In development
Maternal and child nutrition

In development [GID-NG10191] Expected publication date: 21 February 2023

Type

NICE guideline

Status

In development
Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 25 August 2021

Type

NICE guideline

Status

In development
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Proposed [GID-TA10637] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Proposed [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remdesivir for treating COVID-19 [ID3808]

Proposed [GID-TA10721] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Proposed [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bupivacaine–meloxicam for treating postoperative pain [ID2728]

Proposed [GID-TA10716] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating hypereosinophilic syndrome [ID3749]

Proposed [GID-TA10755] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]

Proposed [GID-TA10739] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Proposed [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Proposed [GID-TA10666] Expected publication date: 26 August 2021

Type

Technology appraisal guidance

Status

Proposed
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sotagliflozin for treating type 2 diabetes [ID1657]

Proposed [GID-TA10665] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Proposed [GID-TA10722] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Proposed [GID-TA10691] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Proposed [GID-TA10694] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

Proposed [GID-TA10698] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etranacogene dezaparvovec for treating haemophilia B [ID3812]

Proposed [GID-TA10699] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Proposed [GID-TA10702] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eptinezumab for preventing migraine [ID3803]

Proposed [GID-TA10677] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for general anaesthesia [ID3796]

Proposed [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Proposed [GID-TA10680] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed